Josh Hardman shares Psychedelic Alpha Bulletin 219 updates focused on ibogaine and US policy, research, and legal developments

Ibogaine takes center stage in Psychedelic Alpha Bulletin 219, with a roundup of where US policy and industry momentum are heading. The bulletin covers progress of ibogaine related bills in state legislatures, recent incidents at former ex-US sites, Colorado's potential regulation of the drug, and Gabon's role in potential export and import decisions. It also tracks the state of ibogaine drug development, including a look at DemeRx's fresh Phase 1 data. Beyond ibogaine, the update includes other psychedelics related developments: the Trump administration veto of a Commissioner's National Priority Voucher expected for Compass Pathways' psilocybin efforts, a Delaware lawsuit where Signant Health accuses Definium Therapeutics of trade secret theft, and a scan of Epstein files for psychedelics related threads.